Showing 7371-7380 of 8692 results for "".
- Global Derm Market Reaches $11.6 Billionhttps://practicaldermatology.com/news/20120224-global_derm_market_reaches_116_billion/2459867/The global prescription dermatologic therapy market grew 6.2% from 2009 to 2001, to reach $11.6 billion. A new MarketWatch.com. report notes that the most dramatic gains were in the antiaging/photodamage, hair loss and hair removal, psoriasi
- Ulthera to Expand Operationshttps://practicaldermatology.com/news/20120210-ulthera_to_expand_operations/2459868/Ulthera, Inc. (www.ultherapy.com) is expanding its operations to include the manufacturing of various components of its technology, part of a growth plan anticipated to create more than 100 new, high-wage jobs and result in $1.68 milli
- Laser for Oncychomycosis Clearedhttps://practicaldermatology.com/news/20120202-laser_for_oncychomycosis_cleared/2459872/Recently FDA-cleared for the temporary increase of clear nail in patients with onychomycosis, Sciton's ClearSense handpiece provides optimum laser delivery for JOULE treatment to safely provide effective treatment for ski
- Amarte Relaunches Dermatologist-Formulated Ultra Veil Daily SPF 40https://practicaldermatology.com/news/amarte-relaunches-ultra-veil-daily-spf-40/2483087/Amarte Skin Care has relaunched its flagship sunscreen, ULTRA VEIL® DAILY SPF 40, according to a press release from the manufacturer. The updated product maintains its position as a top-tier hybrid sunscreen, the press release
- Deucravacitinib Shows Sustained Efficacy in Plaque Psoriasis Through 3 Years: Studyhttps://practicaldermatology.com/news/deucravacitinib-shows-sustained-efficacy-in-plaque-psoriasis-through-3-years-study/2483055/Deucravacitinib, a first-in-class oral selective TYK2 inhibitor, has demonstrated durable efficacy and a favorable safety profile in patients with moderate-to-severe plaque psoriasis, according to a recent review of phase III and long-term data.
- Study: AGE-Inhibitor Cream Improves Skin Tone and Firmness Post-Treatmenthttps://practicaldermatology.com/news/study-age-inhibitor-cream-improves-skin-tone-and-firmness-post-treatment/2483017/An AGE-inhibiting moisturizer significantly improved post-procedure facial appearance following glycolic acid peels or radiofrequency microneedling, particularly among women with skin of color. Researchers for the randomized,
- Bimekizumab Outperforms IL-17 Inhibitors in Real-World Psoriasis Studyhttps://practicaldermatology.com/news/bimekizumab-shows-edge-over-il-17-inhibitors-in-polish-real-world-psoriasis-study/2482980/Bimekizumab demonstrated a faster and more robust response than secukinumab and ixekizumab in a real-world cohort of Polish patients with moderate-to-severe plaque psoriasis. Researchers conducted a retrospective analysis fro
- Dr. Ted Rosen on JAK Inhibitors for Refractory Granulomatous and Autoimmune Dermatoseshttps://practicaldermatology.com/news/Dr-Ted-Rosen-JAK-Inhibitors-Refractory-Granulomatous-Autoimmune-Dermatoses/2476038/The role of JAK inhibitors in diseases characterized by chronic macrophage–T-cell interactions continues to grow, Theodore Rosen, MD, said at the DEF Essential Resource Meeting 2025 (DERM2025). The discussion focused on granuloma annulare (GA), sarcoidosis, lichen planus (LP), and lupus erythemat
- Dr. Ted Rosen Highlights Oral Lesions in Dermatologyhttps://practicaldermatology.com/news/Dr-Ted-Rosen-Highlights-Oral-Lesions-Dermatology/2476037/Oral lesions represent a diagnostic challenge in dermatology due to their limited morphological variation and overlapping features across conditions. At the DEF Essential Resource Meeting 2025 (DERM2025), Theodore Rosen, MD, reviewed a broad spectrum of oral pathologies, from benign pigmentations
- Study: Ustekinumab Shows Durability in Real-World Psoriasis Biologic Sequencing Studyhttps://practicaldermatology.com/news/study-ustekinumab-shows-durability-in-real-world-psoriasis-biologic-sequencing-study/2476000/Ustekinumab (Stelara) was associated with the longest treatment duration among biologics used for moderate-to-severe psoriasis, according to results from a recent retrospective real-world analysis. Researchers evaluated health